Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment Abciximab (c7E3 Fab) during percutaneous coronary revascularization

American Journal of Cardiology

Volumn 79, Issue 3, 1997, Pages 286-291

  Lincoff, A Michael ^a   Tcheng, James E ^{a,b,c,d,e,f,g,h,i}   Califf, Robert M ^{a,b,c,d,e,f,g,h,i}   Bass, Theodore ^{a,b,c,d,e,f,g,h,i}   Popma, Jeffrey J ^{a,b,c,d,e,f,g,h,i}   Teirstein, Paul S ^{a,b,c,d,e,f,g,h,i}   Kleiman, Neal S ^{a,b,c,d,e,f,g,h,i}   Hattel, Larry J ^{a,b,c,d,e,f,g,h,i}   Anderson, H Vernon ^{a,b,c,d,e,f,g,h,i}   Ferguson, James J ^{a,b,c,d,e,f,g,h,i}   Cabot, Catherine F ^{a,b,c,d,e,f,g,h,i}   Anderson, Keaven M ^{a,b,c,d,e,f,g,h,i}   Berdan, Lisa G ^{a,b,c,d,e,f,g,h,i}   Musco, Maura H ^{a,b,c,d,e,f,g,h,i}   Weisman, Harlan F ^{a,b,c,d,e,f,g,h,i}   Topol, Eric J ^{a,b,c,d,e,f,g,h,i}  

^a LERNER RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c Kls Martin   (United States)

^d WASHINGTON HOSPITAL CENTER   (United States)

^e SCRIPPS RESEARCH INSTITUTE   (United States)

^f Baylor Coll Med the U Med Ctr   (United States)

^g MEMORIAL HERMANN HOSPITAL   (United States)

^h TEXAS HEART INSTITUTE   (United States)

ⁱ CENTOCOR INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; FEMALE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HEPARINIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MYELIN SHEATH; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADULT; AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CORONARY DISEASE; FEMALE; FIBRINOLYTIC AGENTS; HEMORRHAGE; HEPARIN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PILOT PROJECTS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TREATMENT OUTCOME;

EID: 8044222756     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(96)00749-7     Document Type: Article

References (13)

1. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 330:1994;956-961.
2. Rao AK, Pratt C, Berke A, Jaffe A, Ockene I, Schreiber TL, Bell WR, Knatterud G, Robertson TL, Terrin ML. Thrombolysis in myocardial infarction (TIMI) trial - Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol. 11:1988;1-11.
3. Landefeld LS, Cook EF, Hatley M, Weisberg M, Goldman L. Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. Am J Med. 82:1987;703-713.
4. Harker LA. Platelets and vascular thrombosis. N Engl J Med. 330:1994;1006-1007.
5. Tcheng JE, Ellis SG, George BS, Kereiakes DJ, Kleiman NS, Talley JD, Wang AL, Weisman HF, Califf RM, Topol EJ. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty. Circulation. 90:1994;1757-1764.
6. Aguirre FV, Topol EJ, Ferguson JJ, Anderson K, Blankenship JC, Heuser RR, Sigmon K, Taylor M, Gottlieb R, Hanovich G, Rosenberg M, Donohue TJ, Weisman HF, Califf RM. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention. Circulation. 91:1995;2882-2890.
7. Muller DWM, Shamir KJ, Ellis SG, Topol EJ. Peripheral vascular complications after conventional and complex percutaneous coronary interventional procedures. Am J Cardiol. 69:1992;63-68.
8. Johnson LW, Esente P, Giambartolomei A, Grant WD, Loin M, Reger MJ, Shaw C, Walford GD. Peripheral vascular complications of coronary angioplasty by the femoral and brachial techniques. Cathet Cardiovasc Diagn. 31:1994;165-172.
9. Oweida SW, Roubin GS, Smith RB, Salam AA. Postcatheterization vascular complications associated with percutaneous transluminal coronary angioplasty. J Vasc Surg. 12:1990;310-315.
10. Fail PS, Maniet AR, Banka VS. Subcutaneous heparin in postangioplasty management: comparative trial with intravenous heparin. Am Heart J. 126:1993;1059-1067.
11. Friedman HZ, Cragg DR, Glazier SM, Gangadharan V, Marsalese DL, Schreiber TL, O'Neill WW. Randomized prospective evaluation of prolonged versus abbreviated intravenous heparin therapy after coronary angioplasty. J Am Coll Cardiol. 24:1994;1214-1219.
12. Dougherty KG, Gaos CM, Bush HS, Leachman R, Ferguson JJ. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin. Cathet Cardiovasc Diagn. 26:1992;260-263.
13. McGarry TF, Gottlieb RS, Morganroth J, Zelenkofske SL, Kasparian H, Duca PR, Lester RM, Kreulen TH. The relationship of anticoagulation level and complications after successful percutaneous transluminal coronary angioplasty. Am Heart J. 123:1992;1445-1451.